Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared...
Covered in this story
Call it yourself
No calls on $ADT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ADT →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.